您现在的位置: 首页> 研究主题> 全身热疗

全身热疗

全身热疗的相关文献在1989年到2022年内共计279篇,主要集中在肿瘤学、临床医学、外科学 等领域,其中期刊论文195篇、会议论文11篇、专利文献228942篇;相关期刊132种,包括家庭健康、医疗装备、临床麻醉学杂志等; 相关会议11种,包括世界中联自然疗法研究专业委员会第三届学术年会暨国际热疗医学学会第32届学术年会、世界中联自然疗法研究专业委员会第二届学术年会、全国第二届航海预防医学、海军第八次预防医学专业学术会议等;全身热疗的相关文献由488位作者贡献,包括刘静、李泽华、虞喜豪等。

全身热疗—发文量

期刊论文>

论文:195 占比:0.09%

会议论文>

论文:11 占比:0.00%

专利文献>

论文:228942 占比:99.91%

总计:229148篇

全身热疗—发文趋势图

全身热疗

-研究学者

  • 刘静
  • 李泽华
  • 虞喜豪
  • 汤学林
  • 王远东
  • 刘曼珍
  • 周源
  • 景德明
  • 杜芳
  • 王庆康
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 何媛; 邱俊
    • 摘要: 目的 探讨全身热疗在中晚期结肠癌患者中的应用价值。方法 选择2019年2月~2020年6月广州市花都区人民医院收治的中晚期结肠癌患者80例,按照随机数字法分为两组,每组各40例。对照组行单纯化疗,观察组联合41.8°C全身热疗,比较两组治疗过程中(治疗前、治疗1周后、治疗1个疗程后)的皮质醇水平变化,统计两组实体肿瘤治疗效果,比较两组治疗1年内肿瘤控制率、肿瘤增大率及远处转移率,统计1年期内两组生存情况。结果 治疗1周后和治疗1个疗程后,观察组皮质醇水平分别为(318.02±17.31)pmol/L和(286.32±13.12)pmol/L,均低于对照组的(585.51±22.42)pmol/L和(574.41±21.91)pmol/L(t=59.776和71.402,均P<0.001);观察组完全缓解率为57.5%,高于对照组的27.5%(χ^(2)=7.366,P<0.05),疾病进展率为7.50%,显著低于对照组的30.0%(χ^(2)=5.251,P<0.05),治疗1年内观察组肿瘤控制率为90.00%,高于对照组的67.5%(χ^(2)=4.781,P=0.029<0.05),远处转移率为2.50%,低于对照组的25.0%(χ^(2)=6.746,P=0.009<0.05);随访1年,观察组死亡10例,存活率为75.00%,对照组死亡26例,存活率为35.00%,观察组1年生存率高于对照组(P<0.05)。结论 针对中晚期结肠癌患者联合全身热疗,能有效降低机体应激反应,提高肿瘤控制率,减少治疗远处转移率,延长患者生存时间。
    • 王革芳; 吴成利; 姜程远; 虞喜豪; 王蕾; 朱琴
    • 摘要: Objective To study the short-term efficacy and toxicity of intraperitoneal chemotherapy combined with thermotherapy in the treatment of malignant ascites.Methods A total of 60 patients were randomly divided into control group (30 cases) and study group (30 cases).The control group received intraperitoneal chemotherapy and was given chemotherapy drugs injecting after drainage of ascites,while the study group was given intraperitoneal chemotherapy combined with whole body thermal therapy.The short-term efficacy and toxicity were evaluated.Results The efficacy rate of life quality improvement in the study group was higher than that in the control group (90% vs.60%,P < 0.05).There was no significant difference between the two groups in toxicity (P >0.05).Conclusion Intraperitoneal chemotherapy combined with whole body thermal therapy in the treatment of malignant ascites has higher efficacy and tolerance than intraperitoneal chemotherapy alone.%目的 研究腹腔化疗联合全身热疗对恶性腹腔积液的近期疗效及毒副作用.方法 将60例恶性肿瘤患者随机分为2组,对照组30例接受单纯腹腔内化疗,排空腹水后注入化疗药物,研究组30例接受腹腔化疗联合全身热疗.评价2组患者的近期疗效及毒副反应.结果 研究组生活质量改善有效率为90%,高于对照组的60% (P<0.05).2组毒副反应差异无统计学意义(P>0.05).结论 腹腔内化疗联合全身热疗治疗恶性腹腔积液较单纯腹腔内化疗疗效、耐受性好.
    • 虞喜豪; 朴京虎; 王咏梅; 姜程远; 王建平; 吴小艳
    • 摘要: Objective To investigate the clinical significance of hyperthermia-therapy adjuvant stereotaxic body radiotherapy (SBRT,Gamma-knife / accelerator) in patients with several different re-treating advanced stage cancers.Methods Totally 170 patients with re-treating advanced stage cancers were retrospectively analysed and divided into three groups according to their main therapeutic methods.Among them,99 cases were mainly treated with radiotherapy alone (group A),while 39 cases with combined hyperthermia and radiotherapy (group B) and other 34 cases with hyperthermia alone (group C).The systemic 3-dimensional orientation apparatus was used in radiotherapy.The total dose of 35-65GY was given in synchronous or sequential radiotherapy.WB-1 high-energy-beam microwave thermotherapeutic device was used for hyperthermia on patients mainly by abdominal irradiation.The heating power was set at 500-800W in which body temperature was exposed to elevated temperature of 39.5-41.5°C lasting for 60-90min.Results The overall responses rates(ORR) of three groups were 3.3%,13.5% and 2.9% respectively.Among them,patients with combined hyperthermia-radiotherapy achieved the highest ORR,especially for those with urological,head and neck neoplasms.In addition,patients with radiotherapy alone reached significantly higher average OS as compared with other 2 groups,especially for those with pelvic gynecologic,lung and digestive system tumor.(Average OS in three subsets:6.32m,5.16m and 5.08m,P < 0.01).Nevertheless,the median survival time (MST) was similar in these three groups,with non-significance difference (P > 0.05).Conclusion The hyperthermia -therapy adjuvant stereotaxic radiotherapy could partly increased ORR in certain patients with re-treating advanced cancers,but failed to show significant benefit on OS.A higher average OS was observed in patients with radiotherapy alone.Moreover,no significance difference was observed among different types of cancers regarding MST and OS.Thus,for patients with re-trating advanced stage cances,palliative treatment such as radiotherapy alone may be more practical and effective.%目的 观察并探讨立体定向体部放射治疗(SBRT)辅以微波全身热疗在常见几类复治性晚期肿瘤患者治疗中的临床实际意义及价值.方法 对170余例患者依其主要采用治疗手段以回顾性研究方式,分为单纯放疗组(99例)、热放疗组(37例)及单纯热疗组(34例).放射治疗主要采用60Coγ-刀治疗系统及Rapidac直线加速器精确放疗系统实施治疗.总剂量范围35~65Gy.热疗采用WB-1型高能聚焦微波热疗机行腹部照射透热方式致患者机体体温升高至39.5 ~ 41.5°C,持续60~90min.热放疗联合组为放射治疗周期期间及先后同步予以全身热疗.结果 在各类复治肿瘤患者中,单纯放疗组,热疗放疗组及单纯热疗组肿瘤缓解总有效率(ORR)分别为3.3%、13.5%及2.9%;以放疗结合热疗组略高(与单纯放疗比x2=5.35,P<0.025),其中以泌尿系及头颈肿瘤比例略高.而中位主存期(MST),尤其平均总生存期(0S),在3组不同治疗方式中,以单纯放疗组较高,差异有统计学意义(t =4.04,P<0.01)(OS分别为6.32、5.16、5.08个月),但MST 3组间差异无统计学意义(t=2.05,P >0.05).另观察发现单纯放疗总生存期(0S)略高的复治患者中以盆腔妇科及肺、消化系肿瘤较高.结论 在复治性晚期肿瘤治疗中,立体定位放疗辅以全身热疗,可部分提高肿瘤缓解有效率,但并非取得明显生存获益.总平均生存期OS以仅予单纯放疗者略高,但各瘤种在3组间MST、OS总体差异无统计学意义.对此类晚期癌患者选用单项姑息性减症性治疗(如放疗)可能更有实际临床意义.
    • 王跃
    • 摘要: 目的 探讨全身热疗、化疗联合应用于晚期非小细胞肺癌患者治疗过程中的具体效果及对机体Th1/Th2平衡、IL-2、IFN-γ、IL-4、IL-10、VEGF水平的影响情况.方法 研究组晚期NSCLC患者选择全身热疗+化疗,对照组晚期NSCLC患者选择局部热疗+化疗.结果 研究组临床总有效率(60.00%)显著高于对照组(33.33%),P<0.05;两组治疗前Th1/Th2、VEGF、IL-2、IFN-γ、IL-4、IL-10检测值对比均P>0.05,治疗后研究组Th1/Th2、IL-2、IFN-γ水平提高幅度以及VEGF、IL-4、IL-10水平下降幅度均大于对照组(P<0.05).结论 应用全身热疗、化疗联合治疗晚期NSCLC患者可显著提高其临床疗效,有利于改善相应实验室检查指标.
    • 摘要: 全身热疗是指利用红外线、微波、射频等全身或局部加温方式达到全身热治疗效果的一种治疗手段。1适应证临床确诊的恶性肿瘤,患者能耐受并愿意接受全身热疗;配合放疗、化疗等其他抗肿瘤综合治疗;肿瘤反复术后的预防复发转移治疗;其他治疗后复发或化疗耐药的治疗;晚期全身广泛转移的姑息治疗。
    • 摘要: 全身热疗是指利用红外线、微波、射频等全身或局部加温方式达到全身热治疗效果的一种治疗手段。1适应证临床确诊的恶性肿瘤,患者能耐受并愿意接受全身热疗;配合放疗、化疗等其他抗肿瘤综合治疗;肿瘤反复术后的预防复发转移治疗;其他治疗后复发或化疗耐药的治疗;晚期全身广泛转移的姑息治疗。
    • 张华; 戚锐锋; 张芸; 刘平生; 上官新英; 玛依努尔
    • 摘要: 目的:观察全身热疗联合化疗治疗恶性肿瘤的疗效及不良反应。方法58例恶性肿瘤患者(A组)接受全身热疗联合化疗,全身热疗采用SRI全身热疗系统,温度40°C±0.5°C,持续90~120 min,1次/3周。另外58例(B组)只接受单纯化疗。结果 A组12个月及96个月生存率(82.76%和67.25%)均高于B组(77.60%和50%),且两组比较差异有显著性意义(P0.05)。不良反应主要包括胃肠道反应及骨髓抑制。结论全身热疗联合化疗方案组治疗对恶性肿瘤疗效好,不良反应轻,是治疗恶性肿瘤较好的方案。%Objective To observe the efficacy and toxicity of whole body hyperthermia combined with chemotherapy in the treatment of malignant tumor. Methods 58 patients with malignant tumor were treated by conventional chemotherapy combined with whole body hyperthermia(group A). We used SRI WBH system,and the temperature was (40±0.5)°C,lasting for 90-120 minutes,once per 3 weeks. Another 58 patients received conventional chemotherapy only (group B). Results The overall survival (OS) rates of 12-month and 96-month in group A (82.76%and 67.25%) were higher than that in group B (77.60%and 50%). There was significant difference in OS between the two groups (P<0.05). The median progression-free survival (PFS) in group A (27-month) was longer seven months than group B (20-month). There was significant difference between the two groups (P<0.05). The main toxicities were gastrointestinal tract, and myeloma suppression. Conclusion Whole body hyperthermia combined with chemotherapy has a good anti-tumor activity and tolerable toxicity on malignant tumor patients.
    • 唐滟; 邓力红
    • 摘要: 目的 探讨DP方案双路径化疗联合全身热疗治疗晚期胃癌并恶性腹腔积液的临床疗效.方法 晚期胃癌伴恶性腹腔积液的患者分成观察组及对照组,观察组采用DP方案双路径化疗联合热疗,对照组采用DP方案双路径给药,不行热疗.2周期治疗后评价近期疗效,并定期随访,观察生存期.结果 观察组和对照组腹水控制率分别为80%和57.6%(P <0.05),治疗后观察组较对照组卡氏评分提高(P<0.05),两组消化道及骨髓抑制不良反应差异无统计学意义(P>0.05),患者可耐受.结论 DP方案双路径化疗联合热疗对晚期胃癌恶性腹腔积液的疗效和安全性较好,值得进一步探索和研究.
    • 朱正华
    • 摘要: [目的]建立一套红外线体表热辐射式全身热疗(RWBH)的护理方法。[方法]对63例晚期癌症病人进行 RWBH 辅助治疗,效果根据热疗前后影像学检查对比及临床症状的观察判断。[结果]63例病人中51例(80.9%)病人情况好转,卡氏评分(KPS)提高10分以上,完全缓解(CR)占6.3%,部分缓解(PR)占54.8%,无变化(NC)占20.4%,进展(PD)占18.5%,其余无任何并发症。[结论]RWBH 可以缓解疼痛,合理的护理是全身热疗过程中减少并发症、确保治疗成功的重要环节。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号